Results 61 to 70 of about 3,056 (181)

Operationalizing Alzheimer's disease trials in the era of targeted therapies

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract The therapeutic landscape of Alzheimer's disease (AD) is rapidly evolving with the clinical adoption of anti‐amyloid monoclonal antibodies (mAbs) despite an incomplete understanding of disease mechanisms, progression, and heterogeneity. Designing both observational longitudinal cohorts and clinical trials with novel mAbs in mind is imperative.
Jagan A. Pillai, Suvarna Alladi, Brian S. Appleby, Jared Robert Brosch, Kristian Steen Frederiksen, Douglas Galasko, Oscar L. Lopez, James B. Leverenz, Andrew J. Saykin, Jonathan M. Schott, Sudha Seshadri, Babak Tousi, David A. Wolk   +12 more
wiley   +1 more source

Sex differences in treatment effects of lecanemab and donanemab: A Bayesian reanalysis of CLARITY‐AD and TRAILBLAZER‐ALZ2

Alzheimer’s & Dementia: Translational Research & Clinical Interventions
INTRODUCTION This study investigated evidence for or against a difference in treatment effect between women and men for lecanemab and donanemab. METHODS Data were derived from supplementary analyses of the regulatory studies CLARITY‐AD (lecanemab) and ...
Stefan J. Teipel, Yi Tang, Ara Khachaturian   +2 more
doaj   +1 more source

Digital cognitive phenotyping enhances risk stratification in preclinical Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract INTRODUCTION Amyloid positivity does not reliably predict near‐term cognitive decline in preclinical Alzheimer's disease (AD). We tested whether digital cognitive phenotyping improves prognostic precision. METHODS Baseline performance on a brief self‐administered digital battery was analyzed in 1146 amyloid beta (Aβ)+ and 538 Aβ− cognitively ...
Casey R. Vanderlip, Craig E. L. Stark
wiley   +1 more source

Reply to “CSF Amyloid‐β Risk Stratification in CAA: A Missing Link for Anti‐Amyloid Therapy Safety”

Annals of Neurology, EarlyView.
Philipp Arndt, Stefanie Schreiber
wiley   +1 more source

Rethinking tau‐targeted therapy in Alzheimer's disease: Toward a dual biomarker strategy

Alzheimer's &Dementia, Volume 22, Issue 9, September 2026.
Abstract Tau pathology is more closely associated with cognitive deterioration than amyloid burden in symptomatic Alzheimer's disease (AD), yet tau‐targeted trials have often interpreted decreases in soluble phosphorylated tau (p‐tau) as evidence of therapeutic success. Emerging data argue for a more biology‐informed framework.
Charlotte E. Teunissen, Lorenzo Pini, Bruno P. Imbimbo   +2 more
wiley   +1 more source

Therapeutic Potential of Oxiracetam in Neurocognitive Disorders: A Narrative Review

Brain and Behavior, Volume 16, Issue 9, September 2026.
ABSTRACT Purpose: Cognitive impairment is a growing global health concern associated with aging, neurodegenerative diseases, stroke, and traumatic brain injury. Existing pharmacological treatments, including cholinesterase inhibitors and memantine, provide limited and variable benefits.
Hafsa Ali, Syeda Maliha, Sundas Ishtiaq, Omer Al‐Karawi, Mohammed Hammad Jaber Amin   +4 more
wiley   +1 more source

Metabolic resistance of Aβ3pE-42, a target epitope of the anti-Alzheimer therapeutic antibody, donanemab [PDF]

The amyloid β peptide (Aβ), starting with pyroglutamate (pE) at position 3 and ending at position 42 (Aβ3pE-42), predominantly accumulates in the brains of Alzheimer’s disease.
Robinson, Andrew C, Shirotani, Keiro, Mihira, Naomi, Mann, David MA, Saito, Takashi, Sekiguchi, Misaki, Higuchi, Makoto, Kakiya, Naomasa, Fujioka, Ryo, Watanabe-Iwata, Kaori, Takamura, Risa, Tsubuki, Satoshi, Matsuba, Yukio, Kamano, Naoko, Iwata, Nobuhisa, Hashimoto, Shoko, Watamura, Naoto, Morito, Takahiro, Sasaguri, Hiroki, Saido, Takaomi C   +19 more
core   +3 more sources

Predictors of Alzheimer's disease treatment optimism among a nationally representative sample of US older adults

Alzheimer's &Dementia: Behavior &Socioeconomics of Aging, Volume 2, Issue 3, September 2026.
Abstract INTRODUCTION Treatment optimism—the belief that treatment efficacy will significantly improve over time—has been shown to influence help‐seeking for various diseases. Little is known, however, about treatment optimism in Alzheimer's disease (AD). METHODS The National Poll on Healthy Aging surveyed a nationally representative sample of US older
Sarah McCain, Jonathan M. Reader, J. Scott Roberts   +2 more
wiley   +1 more source

Mild Cognitive Impairment Diagnosis and Care Algorithms and the Role of Digital Interventions: Expert Consensus

CNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Mild cognitive impairment (MCI) carries a risk of further cognitive decline; thus, early diagnosis and intervention are important. The ASCEND Expert Group presents novel algorithms for (1) cognitive assessment/clinical diagnosis and (2) MCI management, emphasizing a multimodal strategy encompassing metabolic/cerebrovascular risk reduction, sensory loss
Nagaendran Kandiah, Yee Fai Chan, Darwin Dasig, Jacqueline Dominguez, Kar Chai Koh, Si Ching Lim, Paulus Anam Ong, Encarnita Raya‐Ampil, Raymond Chee Seong Seet, Vorapun Senanarong, Kit Mun Tan, Maw Pin Tan, Trần Công Thắng, Tong Mai Trang, Yuda Turana, Cuibai Wei, Ralf Ihl   +16 more
wiley   +1 more source

Lecanemab for mild Alzheimer disease – is there a way forward?

Drugs in Context
This Editorial reviews data on the efficacy and adverse effects of lecanemab amongst individuals with mild Alzheimer disease. Additionally, the recent controversy regarding the rejection by the EMA of a marketing authorization request for lecanemab ...
Rajesh R Tampi
doaj   +1 more source